The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
Abstract
integrin to mucosal addressin cell adhesion molecule-1 expressed on the surface of mucosal endothelial cells is a crucial component of the gut-selective homing mechanism for lymphocytes.In contrast, other monoclonal antibodies approved for the treatment of inflammatory bowel diseases, such as tumour necrosis factor α antagonists and the integrin antagonist natalizumab, act systemically or on multiple targets to reduce inflammation.The unique gut selectivity of vedolizumab may contribute to the favourable benefit-risk profile observed in vedolizumab clinical trials. In this review, we summarise data from the preclinical development of vedolizumab and describe the current understanding of the mechanism of action as it relates to other biological therapies for inflammatory bowel disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Self-citationVedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J. V., Sandrock, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107829 · Cited by 1,242
Takada, Y., Ye, X., & Simon, S. (2007) · Genome Biology · doi:10.1186/gb-2007-8-5-215 · Cited by 1,205
Guidelines for the management of inflammatory bowel disease in adults
Carter, M. J., Lobo, A. J., & Travis, S. P. L. (2004) · Gut · doi:10.1136/gut.2004.043372 · Cited by 1,083
Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities
Hanauer, S. B. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000195385.19268.68 · Cited by 968
Natalizumab Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043335 · Cited by 927
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Colombel, J.-F., Sands, B. E., Rutgeerts, P., Sandborn, W., Danese, S., D'Haens, G., Panaccione, R., Loftus, E. V., Sankoh, S., Fox, I., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311079 · Cited by 806
Self-citationTan, C. S., & Koralnik, I. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70040-5 · Cited by 776
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
Sands, B. E., Feagan, B. G., Rutgeerts, P., Colombel, J.-F., Sandborn, W. J., Sy, R., D’Haens, G., Ben-Horin, S., Xu, J., Rosario, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.05.008 · Cited by 715
Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Dubé, R., Cohen, A., Steinhart, A. H., Landau, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042982 · Cited by 692
The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms
Engelhardt, B., & Ransohoff, R. M. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.07.004 · Cited by 673
Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo.
Hamann, A., Andrew, D. P., Jablonski-Westrich, D., Holzmann, B., & Butcher, E. C. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.7.3282 · Cited by 628
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., Spehlmann, M. E., Rutgeerts, P. J., Tulassay, Z., Volfova, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.024 · Cited by 614
Lügering, A., Schmidt, M., Lügering, N., Pauels, H.-G., Domschke, W., & Kucharzik, T. (2001) · Gastroenterology · doi:10.1053/gast.2001.28702 · Cited by 588
Immunopathology of inflammatory bowel disease
Wallace, K. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i1.6 · Cited by 579
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
ten Hove, T. (2002) · Gut · doi:10.1136/gut.50.2.206 · Cited by 545
Trafficking of immune cells in the central nervous system
Wilson, E. H., Weninger, W., & Hunter, C. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41911 · Cited by 524
Briskin, M., Winsor-Hines, D., Shyjan, A. M., Cochran, N. A., Bloom, S. L., Wilson, J., McEvoy, L. M., Butcher, E. C., Kassam, N., Mackay, C. R., et al. (1997) · Europe PMC (PubMed Central) · Cited by 500
Soler, D., Chapman, T., Yang, L.-L., Wyant, T., Egan, R., & Fedyk, E. R. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.153973 · Cited by 456
Self-citationFibronectins, Their Fibrillogenesis, and In Vivo Functions
Schwarzbauer, J. E., & DeSimone, D. W. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005041 · Cited by 445
Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
Major, E. O. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080708.082655 · Cited by 437
Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes.
Erle, D. J., Briskin, M. J., Butcher, E. C., Garcia-Pardo, A., Lazarovits, A. I., & Tidswell, M. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.2.517 · Cited by 355
Hesterberg, P., Winsor-Hines, D., Briskin, M., Soler-Ferran, D., Merrill, C., Mackay, C., Newman, W., & Ringler, D. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8898653 · Cited by 323
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab
Steinman, L. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1752 · Cited by 317
New targets for mucosal healing and therapy in inflammatory bowel diseases
Neurath, M. F. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.73 · Cited by 309
Role of β7 Integrins in Intestinal Lymphocyte Homing and Retention
Gorfu, G., Rivera-Nieves, J., & Ley, K. (2009) · Current Molecular Medicine · doi:10.2174/156652409789105525 · Cited by 292
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Cohen, A., Bitton, A., Baker, J., Dubé, R., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.06.007 · Cited by 285
α4Integrins as Therapeutic Targets in Autoimmune Disease
von Andrian, U. H., & Engelhardt, B. (2003) · New England Journal of Medicine · doi:10.1056/nejme020157 · Cited by 276
Stüve, O., Marra, C. M., Bar-Or, A., Niino, M., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Jerome, K. R., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1383 · Cited by 271
Regional and mucosal memory T cells
Sheridan, B. S., & Lefrançois, L. (2011) · Nature Immunology · doi:10.1038/ni.2029 · Cited by 257
Schweighoffer, T., Tanaka, Y., Tidswell, M., Erle, D. J., Horgan, K. J., Luce, G. E., Lazarovits, A. I., Buck, D., & Shaw, S. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.2.717 · Cited by 253
Steffen, B. J., Butcher, E. C., & Engelhardt, B. (1994) · PubMed · Cited by 214
Parikh, A., Leach, T., Wyant, T., Scholz, C., Sankoh, S., Mould, D. R., Ponich, T., Fox, I., & Feagan, B. G. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21896 · Cited by 210
Self-citationImmunopathogenesis of inflammatory bowel disease
Shih, D. Q., & Targan, S. R. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.14.390 · Cited by 197
Peyrin-Biroulet, L., & Lémann, M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04599.x · Cited by 196
Rott, L. S., Briskin, M. J., Andrew, D. P., Berg, E. L., & Butcher, E. C. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.10.3727 · Cited by 184
Martin, M. D. P. (2008) · Archives of Neurology · doi:10.1001/archneur.65.12.noc80051 · Cited by 181
Wyant, T., Leach, T., Sankoh, S., Wang, Y., Paolino, J., Pasetti, M. F., Feagan, B. G., & Parikh, A. (2015) · Gut · doi:10.1136/gutjnl-2014-307127 · Cited by 177
Self-citationVan den Brande, J. M. H., Koehler, T. C., Zelinkova, Z., Bennink, R. J., te Velde, A. A., ten Cate, F. J. W., van Deventer, S. J. H., Peppelenbosch, M. P., & Hommes, D. W. (2007) · Gut · doi:10.1136/gut.2006.105379 · Cited by 170
Arihiro, S., Ohtani, H., Suzuki, M., Murata, M., Ejima, C., Oki, M., Kinouchi, Y., Fukushima, K., Sasaki, I., Nakamura, S., et al. (2002) · Pathology International · doi:10.1046/j.1440-1827.2002.01365.x · Cited by 169
Inflammation-induced interstitial migration of effector CD4+ T cells is dependent on integrin αV
Overstreet, M. G., Gaylo, A., Angermann, B. R., Hughson, A., Hyun, Y.-M., Lambert, K., Acharya, M., Billroth-MacLurg, A. C., Rosenberg, A. F., Topham, D. J., et al. (2013) · Nature Immunology · doi:10.1038/ni.2682 · Cited by 161
Connor, E. M., Eppihimer, M. J., Morise, Z., Granger, D. N., & Grisham, M. B. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.65.3.349 · Cited by 148
Role of Integrin αE(CD103)β7 for Tissue-Specific Epidermal Localization of CD8+ T Lymphocytes
Pauls, K., Schön, M., Kubitza, R., Homey, B., Wiesenborn, A., Lehmann, P. M., Ruzicka, T., Parker, C. M., & Schön, M. P. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01481.x · Cited by 143
Fedyk, E. R., Wyant, T. L., Yang, L.-L., Csizmadia, V., Burke, K. E., Yang, H., & Kadambi, V. J. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22940 · Cited by 139
Self-citationAmiot, A., & Peyrin‐Biroulet, L. (2014) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x14558193 · Cited by 133
Review: Anti-adhesion molecule therapy for inflammatory bowel disease
Ghosh, S. K., & Panaccione, R. (2010) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x10373176 · Cited by 116
Coisne, C., Mao, W., & Engelhardt, B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803418 · Cited by 115
Structural specializations of α4β7, an integrin that mediates rolling adhesion
Yu, Y., Zhu, J., Mi, L.-Z., Walz, T., Sun, H., Chen, J., & Springer, T. A. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201110023 · Cited by 104
From genetics of inflammatory bowel disease towards mechanistic insights
Graham, D. B., & Xavier, R. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.04.001 · Cited by 97
Control of α4β7 Integrin Expression and CD4 T Cell Homing by the β1 Integrin Subunit
DeNucci, C. C., Pagán, A. J., Mitchell, J. S., & Shimizu, Y. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902407 · Cited by 94
Lichtenstein, G. R. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13479826 · Cited by 93
Cytokine and endothelial cell adhesion molecule expression in interleukin-10-deficient mice
Kawachi, S., Jennings, S. R., Panés, J., Cockrell, A. S., Laroux, F. S., Gray, L. T., Perry, M. A., van der Heyde, H., Balish, E., Granger, D. N., et al. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.5.g734 · Cited by 90
Vedolizumab for the Treatment of Ulcerative Colitis and Crohn‘s Disease
McLean, L. P., Shea‐Donohue, T., & Cross, R. K. (2012) · Immunotherapy · doi:10.2217/imt.12.85 · Cited by 88
Haanstra, K. G., Hofman, S., Estêvão, D. M. L., Blezer, E. L. A., Bauer, J., Yang, L.-L., Wyant, T. L., Csizmadia, V., Hart, B. A. ‘., & Fedyk, E. R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202490 · Cited by 87
Self-citationBoirivant, M., & Cossu, A. (2011) · Oral Diseases · doi:10.1111/j.1601-0825.2011.01811.x · Cited by 81
Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease
Parikh, A., Fox, I. H., Leach, T. S., Xu, J., Scholz, C. R., Patella, M., & Feagan, B. G. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318281f538 · Cited by 80
Milch, C. E., Wyant, T. L., Xu, J., Parikh, A., Kent, W., Fox, I. H., & Berger, J. R. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.08.011 · Cited by 78
Self-citationKilshaw, P. J. (1999) · Molecular Pathology · doi:10.1136/mp.52.4.203 · Cited by 66
In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes
Wyant, T. L., Yang, L., & Fedyk, E. R. (2013) · mAbs · doi:10.4161/mabs.26392 · Cited by 60
Self-citationNatalizumab and progressive multifocal leucoencephalopathy
Berger, J. R. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.058404 · Cited by 57
Erle, D. J., Brown, T., Christian, D., & Aris, R. M. (1994) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.10.3.7509610 · Cited by 55
Allavena, R., Noy, S., Andrews, M., & Pullen, N. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090437 · Cited by 53
Where are we heading to in pharmacological IBD therapy?
Rogler, G. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.005 · Cited by 49
Brown, Furness, Speight, Thomas, Li, ‡., Thornhill, M. H., & Farthing (1999) · Immunology · doi:10.1046/j.1365-2567.1999.00855.x · Cited by 44
Biancheri, P., Sabatino, A. D., Rovedatti, L., Giuffrida, P., Calarota, S. A., Vetrano, S., Vidali, F., Pasini, A., Danese, S., Corazza, G. R., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31828100a4 · Cited by 41
Role of the mucosal integrin αE(CD103)β7 in tissue-restricted cytotoxicity
Smyth, L. J. C., Kirby, J. A., & Cunningham, A. C. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03385.x · Cited by 35
Jenkinson, S. E., Whawell, S. A., Swales, B. M., Corps, E. M., Kilshaw, P. J., & Farthing, P. M. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03352.x · Cited by 32
Madcam-1 Expression and Regulation in Murine Colonic Endothelial Cells in Vitro
Ando, T., Jordan, P., Wang, Y., Itoh, M., Joh, T., Sasaki, M., Elrod, J. W., Carpenter, A. C., Jennings, M. H., Minagar, A., et al. (2005) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000160807.53858.1c · Cited by 27
Tumor Necrosis Factor-Alpha Antagonists Twenty Years Later
Akobeng, A. K., Sandborn, W. J., Bickston, S. J., Chande, N., Shackelton, L. M., Nelson, S., & Feagan, B. G. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000218 · Cited by 18
Etrolizumab for induction of remission in ulcerative colitis
Rosenfeld, G. A., Parker, C. E., MacDonald, J. K., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011661.pub2 · Cited by 10
Sands, B. E., Cohen, R. D., Isaacs, K. L., Fedorak, R. N., Abhyankar, B., Sankoh, S., & Smyth, M. D. L. (2015) · Gastroenterology · doi:10.1016/s0016-5085(15)30763-0 · Cited by 7
Self-citation
Cited by
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Sands, B. E., Peyrin-Biroulet, L., Loftus, E. V., Danese, S., Colombel, J.-F., Törüner, M., Jonaitis, L., Abhyankar, B., Chen, J., Rogers, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1905725 · Cited by 754
Self-citationTreatment of Inflammatory Bowel Disease: A Comprehensive Review
Cai, Z., Wang, S., & Li, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.765474 · Cited by 675
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234
Metadata
- Authors
- Wyant, T., Fedyk, E., & Abhyankar, B.
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06-01
- Volume
- 10
- Issue
- 12
- Pages
- 1437-1444
- ISSN
- 1873-9946 (ISSN-L)
- 1876-4479
- OpenAlex
- W2414026316
- Cited by
- 284
- References
- 77
- FWCI
- 12.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.